Phase 2 Start

XBIT: Phase 2 Start: Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Efficacy and Safety of V

Name: Phase 2 Start: Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Efficacy and Safety of V
Start: 2026-09-01
End: 2026-09-01

September 1, 2026 · vilamakitug. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: September 1, 2026
Company: XBiotech Inc. (XBIT)
Drug: vilamakitug

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 2 Start~month

Phase 2 Start: Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Efficacy and Safety of V

September 1, 2026

XBIT overview →

Company: XBiotech Inc. (XBIT)
Drug: vilamakitug
Indication: Ankylosing Spondylitis; Axial Spondyloarthritis; r-axSpA